2021-02-18 // Public Health-focused Adjuvant Capital, Backed by Merck & Gates, Raises $300m

Go to Article

2021-02-18 // Investors put $300 million into Adjuvant Capital as global health innovation shines

Go to Article

2021-02-18 // New $300 Million Venture Fund Spotlights Role Of Women In Venture Capital And Public Health

Go to Article

2021-02-18 // Investment firm raises $300M to fund medical research for overlooked diseases

Go to Article

2020-12-14 // Codagenix, Serum Institute to begin UK trials of nasal COVID-19 vaccine in January

Go to Article

2020-10-15 // Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital

Go to Article